Therefore, it can be hypothesized that increased HER2 signaling in patients with HER2+ breast cancer can enhance miR-21 expression in tumor cells and subsequently contribute to the increased serum miR-21 levels by being released into the extracellular space. The gene discussed is ERBB2; the disease is breast cancer.